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ABSTRACT
Two known 13,28-epoxy-oleanane triterpene saponins (1) and (2), were isolated from the 95% 
ethanolic extract of the roots of Myrsine coriaceae and Myrsine andina. Their structures were 
deduced by combined spectral analysis and chemical evidences based on data reported in the 
literature. Compounds 1 and 2 were evaluated in vitro against different cellular models such as 
Mycobacterium tuberculosis, Leishmania amazonensis axenic amastigotes, six human cancer 
cell lines (Hs683, T98G, U251, HT29, MCF7, SKMEL28) and two murine cell lines (CT26 
and B16F10). Compound 1 was found to exhibit antileishmanial activity (IC  = 16 µg/mL) 50
whereas compound 2 was inactive (IC  > 50 µg/mL). Furthermore, compound 1 exhibited 50
stronger inhibition activity on human cancer cells (IC  = 15 µg/mL) and on murine cell lines 50
(IC  = 10 µg/mL) than compound 2 (IC  > 82 and 42 µg/mL, respectively). As the only 50 50
difference between 1 and 2 is due to a substitution of an aldehyde group by a hydroxymethyl 
moiety, these results showed the crucial role of the aldehyde function at C-30 for the 
cytotoxicity. In contrast, none of the tested compounds revealed activity against M. 
tuberculosis.  
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RESUMEN
Dos saponinas triterpénicas de tipo 13,28-epoxi-oleanano (1) y (2), han sido aisladas a partir 
del extracto etanólico al 95% de las raíces de Myrsine coriaceae y Myrsine andina. Las 
estructuras fueron establecidas mediante la combinación de técnicas espectrales y evidencias 
químicas con datos reportados en la literatura. Los compuestos 1 y 2 fueron evaluados con 
ensayos biológicos in vitro frente a diferentes modelos celulares, tales como Mycobacterium 
tuberculosis, amastigotes axénicos de Leishmania amazonensis , macrófagos extraídos del 
peritoneo de ratón, seis líneas celulares de cáncer humano (Hs683, T98G, U251, HT29, MCF7, 
SKMEL28) y dos líneas de células murinas (CT26 y B16F10). El compuesto 1 mostró una 
buena actividad antileishmania (IC  = 16 µg/mL) mientras que el compuesto 2 no mostró 50
actividad alguna (IC > 50 µg/mL). Por otra parte, el compuesto 1 mostró una mayor actividad 50
de inhibición de las células cancerosas humanas (IC  = 15 µg/mL) y en líneas celulares de 50
ratón (IC  = 10 µg/mL) que el compuesto 2 (IC > 82 y 42 µg/mL, respectivamente). Como la 50 50
única diferencia entre 1 y 2 se debe a una sustitución de un grupo aldehído por un grupo 
hidroximetilo, estos resultados demuestran el papel esencial de la función aldehído en C-30 
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para la citotoxicidad. En contraste, ninguno de los compuestos ensayados reveló actividad 
frente a M. tuberculosis.
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INTRODUCTION
Infectious diseases such as leishmaniasis and tuberculosis (TB), commonly being considered as 
neglected diseases, are prevalent in Third World countries. Because most of the affected 
population live in developing countries and cannot afford existing drugs, both diseases have 
been ignored by pharmaceutical industry. Leishmaniasis is a parasitic protozoal disease caused 
by parasites belonging to the genus Leishmania, occurring in subtropical and tropical regions. 
An estimated 12 million people are infected worldwide in 88 countries with an annual incidence 
1,2of about 2–3 million.  Clinically, leishmaniasis occurs in visceral, cutaneous and 
mucocutaneous forms, 90% of the latter occurring in Bolivia, Brazil and Peru. It is a major 
public health problem in tropical and subtropical regions for which development of drug 
resistance by the parasites has worsened this problem. In the absence of effective vaccines, 
3chemotherapy still plays a critical role in treating this disease.
As far as TB is concerned, this is a common and in some cases deadly infectious disease, caused 
by an important intracellular pathogen Mycobacterium tuberculosis. This disease causes 2 
million deaths per year worldwide, with 98% occurring in developing countries. One of the 
4,5highest incidence rates in the Americas occurs in Peru.  Current standard treatments for 
tuberculosis include antibacterial drugs such as Rifampin and Isoniazid, which require between 
six to twelve month-therapies to fully eliminate Mycobacterium from the body. As very few 
treatments are available, there is an urge to discover new treatments with less toxicity and low 
manufacturing costs.
Cancer, responsible for 7.6 million deaths worldwide in 2008 with approximately 70% 
6occurring in low- and middle-income countries, represents another major health issue.  In such 
7a-d 8countries.  including Peru,  some plant extracts are used to combat various types of cancers 
and provide evidence that plants represent a major reservoir within which we may identify 
9a-cnovel anticancer drugs.  
In the course of our investigations on compounds with pharmacological properties and since it 
has been shown that the 13,28-epoxy bridge in the saponin skeleton was putatively assigned as 
10crucial for antileishmania activity,  we carried out a literature search in order to find saponins 
showing the same structural features as the Maesabalides. These compounds, possessing a 
1113,28-epoxy-oleanane bridge and isolated previously from Maesa balansae (Myrsinaceae),  
12 13have been shown to possess potent and highly speci?c in vitro  and in vivo  antileishmania 
14activity. Vermeersch et al., (2009)  reviewed all those saponins from Myrsinaceae, 
Primulaceae, Aceraceae and Icacinaceae families possessing a completely saturated 
pentacyclic triterpene skeleton and a 13,28-epoxy bridge, in which C(28) was a methylene or a 
hydroxymethylene group, excluding the C(28) carbonyl derivatives. For all the studied plants, a 
clear correlation was found between the presence of close analogue 13,28-epoxy-oleanane 
triterpene saponins and a potent and selective antileishmania activity. Furthermore, Aegicerin, 
an oleanane-type pentacyclic triterpene skeleton with this 13,28-epoxy bridge, has shown a 
consistently high level of activity against a large panel of both sensitive and resistant strains of 
15M. tuberculosis .
In this article, we report the isolation and structure elucidation of two known triterpenoid 
saponins, Ardisiacrispin B (1) and Ardisicrenoside A (2), previously isolated from several 
16,17Myrsinaceae plants.  Both compounds were found to possess the 13,28-epoxy bridge 
12 13previously demonstrated as crucial for antileishmanial activity in vitro  and in vivo.  We 
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evaluated their activity in vitro against Leishmania amazonensis axenic amastigotes alongside 
other pathogenic cellular model, e.g. Mycobacterium tuberculosis, as well as two mouse and six 
human cancer cell lines. 
To the best of our knowledge, this is the ? rst report of the isolation of saponins from the Myrsine 




Optical rotations were measured on a Perkin–Elmer 241 polarimeter with a sodium lamp (k = 
589 nm) in a 1 cm microcell. The structures of the isolated compounds were identified by 
nuclear magnetic resonance (NMR; Bruker Avance 500 equipped with a TBI z-gradient 5 mm 
1 13probe). H NMR (500 MHz), C NMR (125 MHz), and 2D-NMR analysis in C D N; NMR 5 5
experiments were performed at 298 K using standard pulse sequences. Chemical shifts () are 
given in ppm relative to TMS with coupling constant (J) reported in Hz. ESI-MS (positive and 
negative-ion mode) spectra were recorded on an ion trap LCQ Finnigan spectrometer. Column 
chromatography and medium-pressure column chromatography were performed on silica gel 
60 SDS 70–200 m and 6–35 m, respectively. TLC was carried out on precoated silica gel 60 
F254 aluminium plates (Merck). Spots were detected under UV (254 and 366 nm) before 
spraying with diphenylborate reagent or a vanillin sulfuric solution followed by heating the 
plate at 110 °C. All solvents were spectral grade or distilled from glass prior to use. 
  
Plant material
The roots of Myrsine andina (Mez.) Pipoly and Myrsine coriacea (Sw.) R. Br. ex Roem. & 
Schult were collected near Oxapampa, Chacos, Peru by M. Haddad, C. Amasifuen, J. Mateo, J. 
Perea in July 2009, and identi?ed by the botanists J. Mateo and C. Amasifuen.  A voucher 
specimen of each (3472 and 1207, respectively) were deposited at the National Herbarium of 
the San Marcos University in Lima, Peru (UNMSM).
  
Extraction and isolation
The air-dried and powdered roots of Myrsine andina and Myrsine coriacea (500 g and 300 g, 
respectively) were exhaustively macerated with 95% EtOH (3 x 3 L) at room temperature to 
yield 29.1 g and 52.8 g of crude extract after evaporation of the solvent in vacuo, respectively. 
Both residues were dissolved in the least amount of MeOH and the solution was diluted with 
tenfold amount of diethyl-ether to precipitate 2 g and 2.3 g of crude saponin mixture, 
respectively, and then partitioned with n-BuOH saturated with H O (3 x 500 mL). The 2
combined n-BuOH extract was evaporated under vacuum to dryness to afford the n-BuOH layer 
residue (1.1 g and 1 g, respectively). The saponin rich precipitates (1.1 and 1 g, respectively) 
were collected by ? ltration and fractionated by successive MPLC (silica gel 60, (15–40 µm), 
CHCl –MeOH–H O 7.5:2.5:0.25 and CHCl  – MeOH – H O 8:2:0.25) to yield 1 and 2. 3 2 3 2
  
Compound 1: Ardisiacrispin B
1 13White amorphous powder. H-NMR (C D N, 500 MHz) and C-NMR (C D N, 125 MHz), 5 5 5 5
+(tables 1); ESI-MS (positive-ion mode) m/z 1097 [M + Na] , ESI-MS (negative-ion mode)     
- - -m/z 1073 [M – H] , 927 [(M – H) – 146] , 765 [(M – H) – 146 – 162] , 603 [(M – H) – 146 – 162 – 
- -162] , and 471 [(M – H) – 146 – 162 – 162 – 132] .
   
Compound 2: Ardisicrenoside A
1 13White amorphous powder. H-NMR (C D N, 500 MHz) and C-NMR (C D N, 125 MHz), 5 5 5 5
+(tables 1); ESI-MS (positive-ion mode) m/z 1099 [M + Na] . ESI-MS (negative-ion mode) m/z 
- - -1075 [M – H] , 929 [(M – H) – 146] , 767 [(M – H) – 146 – 162]  and 605 [(M – H) – 146 – 162 – 
-162] .
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Table 1. NMR Spectroscopic data of aglycon and sugar moieties of compounds 1 and 2.
Aglycone 1 2 Sugar 1 2
δH δC δH δC δH δC δH δC
1 0.81, 1.61 38.9 0.79, 1.61 38.9 Ara 1 4.95 104.2 4.94 104.2
2 1.82, 1.99 26.3 1.81, 1.98 26.4 2 4.59 80.6 4.58 80.5
3 3.13 br d (9.0) 88.8 3.11 br d (9.2) 88.8 3 4.49 72.2 4.49 72.0
4 - 39.5 - 39.5 4 4.58 74.4 4.58 74.4
5 0.62 55.4 0.62 55.4 5 3.79, 4.39 63.4 3.79, 4.40 63.4
6 1.37,  b 17.7 1.38, b 17.7 Glc-1 5.37 d (7.5) 105.2 5.37 d (7.7) 105.2
7 1.49,  b 34.3 1.50, b 34.1 2 4.07 76.2 4.07 76.2
8 - 44.0 - 42.4 3 4.29 77.9 4.23 77.9
9 1.22 50.1 1.23 50.3 4 4.22 71.5 4.13 71.6
10 - 36.7 - 36.7 5 4.06 77.8 4.06 77.9
11 1.70, nd 18.8 1.39, 1.72 18.9 6 4.38, b 62.6 4.38, 4.49 62.4
12 1.52, 1.94 32.1 1.46, 2.10 32.7 Glc-1' 5.23 d (7.5) 102.9 5.24 d (7.4) 102.9
13 - 86.1 - 86.3 2' 4.28 77.7 4.28 77.0
14 - 42.3 - 44.4 3' 4.19 79.4 4.20 79.4
15 1.24, 2.15 36.6 1.50, 2.24 36.8 4' 4.13 71.6 4.14 71.6
16 4.20 77.7 4.20 76.9 5' 3.79 78.2 3.60 77.6
17 - 43.9 - 44.4 6' 4.29, 4.45 62.4 4.30, 4.46 62.3
18 2.06 50.9 1.85 50.9 Rha-1 6.41 br. s 101.5 6.42 br. s 101.4
19 2.82, nd 33.1 2.03, 2.76 33.2 2 4.50 72.5 4.73 72.2
20 - 48.2 - 36.6 3 4.68 72.4 4.69 72.6
21 2.52, 2.66 30.3 1.68, 2.59 32.4 4 4.25 79.0 4.28 74.6
22 1.55, nd 32.1 1.67, 1.87 31.5 5 5.05 69.2 5.04 69.2
23 1.15 27.5 1.14 27.5 6 1.79 18.2 1.80 18.7
24 1.10 16.3 1.00 16.3
25 0.80 16.3 0.80 16.2
26 1.26 18.3 1.31 18.3
27 1.52 19.6 1.58 19.5
28 3.15, 3.57 77.5 3.30, 3.60 77.7
29 1.00 23.9 1.33 28.8
30 9.60 207.3 3.74, 3.99 65.7
a 1 13 1H (500 MHz) and C NMR  (125 MHz) data of 1 and 2 in C D N. The assignments were based on DEPT, H , 5 5
1H-COSY, TOCSY, NOESY, HMQC and HMBC experiments. 
b Not determined.
Bioassays
18Compounds 1 and 2 were evaluated against L. amazonensis axenic amastigotes in vitro  and 
15against M. tuberculosis in vitro . Two independent experiments were carried out to determine 
the in vitro growth inhibitory activity of compounds 1 and 2 in cancer cell lines. This growth 
inhibitory activity was determined by means of the sulforhodamine B (SRB) assay method 
19a-b; 20a-dand the MTT colorimetric assay, respectively, as detailed previously.  
RESULTS
Extraction of the roots of Myrsine andina (Mez.) Pipoly and Myrsine coriacea (Sw.) R. Br. ex 
Roem. & Schult and puri?cation of the extract as described in the experimental section yielded 
compounds 1 and 2. The elucidation of their structures was performed mainly by 500 MHz 
NMR analysis, including 1D- and 2D-NMR (COSY, TOCSY, NOESY, HSQC, HMBC), and 
mass spectrometry.
Compound 1 was obtained as a white crystalline powder with molecular formula C H O  53 86 22,
which was determined by analysis of the MS data. Its positive ESI-MS showed the 
+pseudomolecular ion peak at m/z 1097 [M + Na] . This was con?rmed from its negative ion 
-ESI-MS that showed the quasimolecular ion peak at m/z 1073 [M – H] . Other fragment ion 
- -peaks were observed at m/z 927 [(M – H) – 146] , 765 [(M – H) – 146 – 162] , 603 [(M – H) – 
- - 146 – 162 – 162] , and 471 [(M – H) – 146 – 162 – 162 – 132] corresponding to the successive 
loss of one deoxyhexosyl, two hexosyl and one pentosyl moieties, respectively. 
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13Of the 53 carbons in the C-NMR spectrum (pyridine-d ), 30 were assigned to the triterpenoid 5
skeleton and 23 to the oligosaccharide moiety. Among the 30 carbons of the triterpene 
13skeleton in the C-NMR spectrum, 6 were assigned to the methyl carbons at δ 16.3, 16.3, C
18.3, 19.6, 23.9 and 27.5 ppm, and the methyl protons were identified by the HSQC 
experiments at δ1.10, 0.80, 1.26, 1.52, 1.00 and 1.15 ppm, respectively. Two methine carbons H 
bearing oxygen were found at δ 88.8 and 79.4 ppm. The structural assignment was initiated C
from the long-range coupling networks observed between the methyl protons and the adjacent 
carbons from the HMBC experiments. Extensive NMR analysis (table 1) showed that the 
aglycone was an oleanane skeleton with an oxygen bridge between Agly- 13 (δ 86.1) and C
Agly-28 (δ 77.5). This was confirmed by comparison of the NMR data with known spectral C 11, 21, 22data for structurally related compounds.
The HMBC correlations between two angular methyl groups at δ 1.10 (3H, s, Me(24)) and   H
δ 1.15 (3H, s, H–C(23)) with δ 88.8 (C(3)) con?rmed the location of the ? rst secondary H C
alcoholic function at Agly-3. The absolute con?guration of Agly-3 and Agly-16 was 
determined from a NOESY experiment: cross-peaks at δ 3.13 (1H, d, J = 9.0, Agly-3)/ δ 0.62  H H
(1H, br. d, J = 12.0, Agly-5), and δ 4.20 (1H, br. s, Agly-16)/ δ 1.26 (3H, s, Me(26)), H H
con?rmed the absolute con?guration of the aglycone. Based on these findings, the aglycone 
was identified as 3β,16α dihydroxy-13β,28-epoxyoleanane. 
1The H-NMR spectrum of 1 displayed signals for four anomeric protons at δ 4,94 (d, J = 4,27 H
Hz), 5,24 (d, J = 7,91 Hz), 5,37 (d, J = 7,63 Hz), 6.41 (H, br. s), which correlated with the 
carbon signals at δ 104.2, 102.9, 105.2, and 101.5, respectively, in the HSQC spectrum. C
The ring protons of the monosaccharide residues were assigned starting from the anomeric 
protons by means of the COSY, TOCSY, HSQC, and HMBC NMR plots (table 1), and the 
sequence of the oligosaccharide chains was obtained from the HMBC and NOESY 
experiments. All the protons within each spin system were delineated using COSY with the 
13aid of TOCSY and NOESY spectra. After assignments of the protons, the C-NMR 
resonances of each sugar unit were identified by HSQC and further confirmed by HMBC. 
HPTLC of the acid hydrolysate of 1 in comparison with reference sugars, NMR data of related 11,21structures  lead to the identification of the four monosaccharide units as β-D-glucose (Glc 
x2), one α-L-arabinose (Ara), and one α-L-rhamnose (Rha). The COSY and TOCSY spectra 
confirmed the presence of the one α-rhamnopyranosyl (Rha) from their typical pattern in the 23,24COSY spectrum  and the α-configuration of this latter was also confirmed by observation 
of NOESY correlations between δ (Rha-1), δ (Rha-3), and δ (Rha-5). This information was H H H
confirmed by the δ (Rha-1) non-splitting pattern of rhamnose unit and the three-bond HMBC C
correlations from δ(Rha-1) to δ(Rha-3) and δ(Rha-5) indicated that its anomeric H-atom H C C 
1 25was equatorial, thus possessing an α-configuration in the C  form.  4
3The relatively large J  values of the Glc (7.5–7.8), indicated a β anomeric orientation for H-1,H-226the Glc.  
A cross peak observed in the NOESY spectrum at δ 4.94 (1H, d, J = 4.27, Ara-1)/  3.13 (1H, H H
br. d, J = 9.0, Agly-3), revealed a substitution at C(3) of the aglycon by an arabinosyl moiety. 
This was confirmed by a correlation observed in the HMBC spectrum between an anomeric 
signal at δ 4.94 (1H, d, J = 4.27, Ara-1) and δ 88.8 (Agly-3) and by the reverse correlation at H C
δ 3.13 (1H, br. d, J = 9.0, Agly-3) and δ 104.20 (Ara-1). The HMBC correlation between     H C
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δ 5,37 (d, J = 7,63 Hz, Glc-1), and δ 80.6 (Ara-2) and the reverse correlation at δ 4.59 (1H, H C H
m, Ara-2) and (C) 105.2 (Glc-1) indicated that Glc was linked to C(2) of Ara. This was also 
confirmed by a NOESY cross peak between δ 5,37 (d, J = 7,63 Hz, Glc-1) and δ 4.59 (1H, m, H H
Ara-2). Furthermore, the HMBC correlation between δ 5.23 (1H, d, J = 7.91, Glc-1')) and δ H C
74.4 (Ara-4), together with the reverse correlation at δ 4.58 (1H, m, Ara-4) and δ 102.9 (Glc-H C
1')) and the NOESY correlation between δ 5.23 (1H, d, J = 7.5, Glc-1') and δ 4.58 (1H, m, H H
Ara-4) established the (14) linkage between Glc' and Ara. The substitution of the 
glucopyranosyl moiety at the δ Glc-2') position by a rhamnopyranosyl residue was deduced H
according to the reverse correlations in the HMBC spectra at δ 6.41 (1H, br. s, Rha-1)/ δ 77.7 H C
(Glc-2') and δ 4.28 (1H, m, Glc-2')/ δ 101.5 (Rha-1)), together with the additional NOESY H C
cross-peaks at δ 6.41 (1H, br. s, Rha-1)/ δ 4.28 (1H, m, Glc-2'). H H
On the basis of the above results, the structure of 1 was elucidated as 3-β-Oα-l-
rhamnopyranosyl (1→2)-β-D-glucopyranosyl (1→3)-[β-D-glucopyranosyl (1→2)]-β-d-
arabinopyranosyl}-16α-hydroxy-13β,28-epoxy-oleanane.
Compound 2 was obtained as a white crystalline powder with molecular formula C H O  53 88 22
that was determined by analysis of the MS data. Its positive ESI-MS showed the 
+pseudomolecular ion peak at m/z 1099 [M + Na] . This was con?rmed from its negative ion 
-ESI-MS that showed the quasimolecular ion peak at m/z 1075 [M – H] . Other fragment ion 
- -peaks were observed at m/z 929 [(M – H) – 146] , 767 [(M – H) – 146 – 162]  and 605 [(M – H) – 
-146 – 162 – 162]  corresponding to the successive loss of one deoxyhexosyl and two hexosyl, 
respectively. 
13Of the 53 carbons in the C-NMR spectrum (pyridine-d ), 30 were assigned to the triterpenoid 5
skeleton and 23 to the oligosaccharide moiety. 
13Among the 30 carbons of the triterpene skeleton in the C-NMR spectrum, 6 were assigned to 
the methyl carbons at δ 16.2, 16.3, 18.3, 19.5, 27.5 and 28.8 ppm, and the methyl protons were C
identified by the HSQC experiments at δ0.80, 1.00, 1.31, 1.58, 1.14 and 1.33 ppm, H 
respectively. Two methine carbons bearing oxygen were found at δ 88.8 and 76.9 ppm. The C
structural assignment was initiated from the long-range coupling networks observed between 
the methyl protons and the adjacent carbons from the HMBC experiments. Extensive NMR 
analysis (table 1) showed that the aglycone was an oleanane skeleton with an oxygen bridge 
between Agly-13 (δ 86.3) and Agly-28 (δ 77.7). This was confirmed by comparison of the C C 11, 21, 22NMR data with known spectral data for structurally related compounds.
The HMBC correlations between two angular methyl groups at δ 1.00 (3H, s, Me-24) and δ H H
1.14 (3H, s, Me-23) with δ 88.8 (Agly- 3) con?rmed the location of the ? rst secondary C
alcoholic function at C(3). The absolute con?guration of Agly-3 and Agly- 16 was determined 
from a NOESY experiment: cross-peaks at δ 3.11 (1H, d, J = 9.2, Agly-3)/ δ 0.62  (1H, br. d, H H
J = 12.0, Agly-5), and δ 4.20 (1H, br. s, Agly- 16)/ δ 1.31 (3H, s, Me(26)), con?rmed the H H
absolute con?guration of the aglycone. Based on these findings, the aglycone was identified 
as 3β,16α dihydroxy-13β,28-epoxyoleanane.
Biological activities of. 13,28 – epoxyoleanane triterpene saponins from two peruvian Myrsinaceae
194
Rev Soc Quím Perú. 78 (3) 2012 
C. Girardi, P. Vásquez-Ocnin, D. Castillo, M. Sauvain, R. Rojas, N. Fabre, M. Haddad
Experiments were conducted on axenic amastigotes of Leishmania amazonensis (strain 
16MHOM/BR/76/LTB-012) according to Estevez et al.  
17Evaluation of the antimycobacterial activity in vitro was performed using the TEMA method  against 
MDR and sensitive strains of Mycobacterium tuberculosis. 
 
  
1The H NMR spectrum of 2 displayed signals for four anomeric protons at δ 4.94 (d, J = 4.27 H
Hz), 5.24 (d, J = 7.42 Hz), 5.37 (d, J = 7.71 Hz), 6.42 (1H, br. s), which correlated with the 
carbon signals at δ 104.2, 102.9, 105.2, and 101.4, respectively, in the HSQC spectrum. C
The ring protons of the monosaccharide residues were assigned starting from the anomeric 
protons by means of the COSY, TOCSY, HSQC, and HMBC NMR plots (table 1), and the 
sequence of the oligosaccharide chains was obtained from the HMBC and NOESY 
experiments. All the protons within each spin system were delineated using COSY with the aid 
13of TOCSY and NOESY spectra. After assignments of the protons, the C-NMR resonances of 
each sugar unit were identified by HSQC and further confirmed by HMBC. HPTLC of the acid 11, 21hydrolysate of 2 in comparison with reference sugars, NMR data of related structures  lead 
to the identification of the four monosaccharide units as β-D-glucose (Glc x2), one α-L-
arabinose (Ara) and one α-L-rhamnose (Rha). The COSY and TOCSY spectra confirmed the 
presence of the one α-rhamnopyranosyl (Rha) from their typical pattern in the COSY 23, 24spectrum  and the -configuration of this latter was also confirmed by observation of NOESY 
correlations between Rha-1, Rha-3, and Rha-5'. This information was confirmed by the Rha-1 
non-splitting pattern of rhamnose unit and the three-bond HMBC correlations from H– Rha-1 
to Rha-3 and Rha-5 indicated that its anomeric H-atom was equatorial, thus possessing an -
1 25configuration in the C  form.  4
3The relatively large J  values of the Glc (7.5–7.8), indicated a β anomeric orientation for H-1,H-226the Glc . 
1 13The H- and C-NMR signals of 2 assigned from 2D-NMR spectra were almost 
superimposable on those of 1, except for the disappearance of the signals corresponding to the 
aldheyde group (δ 207.3, C-30) replaced by a hydroxymethyl function (δ 65.7) (table 1). C C
On the basis of the above results, the structure of 2 was elucidated as 3-β-Oα-l-
rhamnopyranosyl (1→2)-β-D-glucopyranosyl (1→3)-[β-D-glucopyranosyl (1→2)]-β-d-
arabinopyranosyl}-16α-hydroxy-30-hydroxymethyl-13β,28-epoxy-oleanane.
Compounds 1 and 2 were evaluated in vitro against different cellular models such as 
15 16Mycobacterium tuberculosis , Leishmania amazonensis axenic amastigotes , mouse 
peritoneal macrophages, six human cancer cell lines (Hs683, T98G, U251, HT29, MCF7, 
SKMEL28) and two murine cell lines (CT26 and B16F10) (table 3).
The experiment has been carried twice with 4 
replicates per experimental condition
The experiment has been carried once with 6 
replicates per experimental condition
Table 2. Antimycobacterial (MIC µg/mL) and antiprotozoal (IC  µM) activity.50
Compounds M. tuberculosis L. amazonensis amastigotes
H37Rv MDR
1 > 25 > 25 16.0
2 > 25 > 25 > 50
Anf.a - - 0.2
Inh.b 0.125 32.0 -
a bAmphotericin B. Isoniazid.
Table 3. In vitro growth inhibition determined in 2 mouse and 6 human 
cancer cell lines.
Compounds
IC50 growth inhibitory concentrations (µM) after 72 h of treatment of 
human cancer cells with the compounds
Hs683 T98G U251 HT-29 MCF-7 SKMEL-28 m 
1 19 22 17 6 22 7 15
2 38 > 100 55 > 100 > 100 > 100 > 82
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Compounds
IC50 growth inhibitory concentrations (µM) after 72 h of treatment of 
murine cancer cells with the compounds
CT-26.WT B16F10 m 
1 15 4 10
2 44 40 42
These experiments have been carried out in the Laboratory of Toxicology – Faculty of Pharmacy – 
Université Libre de Bruxelles (Brussels, Belgium) using the MTT colorimetric assay to determine the IC  50
growth inhibitory concentrations of compounds 1 and 2 in 2 mouse (CT-26.WT and B16F10) and 6 human 
cancer cell lines. These cell lines included the Hs683 oligodendroglioma (obtained from the American 
Type Culture Collection [ATCC], Manassas, VA; code HTB-138), the T98G glioblastoma (ATCC code 
CRL-1690), the U251 glioblastoma (ECACC code 09063001), the HT-29 colon cancer (ATCC code HTB-
38), the MCF-7 breast cancer (Deutsche Sammlung von Mikroorganismen and Zellkulturen [DSMZ], 
Braunschweig, Germany; code ACC115), the SKMEL-28 melanoma (ATCC code HTB-72), the 
Compound 1 was found to exhibit antileishmanial activity (IC  = 16 µg/mL) whereas 50
compound 2 was inactive (IC  > 50 µg/mL). Furthermore, compound 1 exhibited stronger 50
inhibition activity on human cancer cells (IC  = 15 µg/mL) and on murine cell lines (IC  = 10 50 50
µg/mL) than compound 2 (IC  > 82 and 42 µg/mL, respectively). As the only difference 50
between 1 and 2 is due to a substitution of an aldehyde group by a hydroxymethyl moiety, 
these results showed the crucial role of the aldehyde function at C-30 for the cytotoxicity. The 
possibility remains that this growth inhibitory activity is related to compound 1 and 2 
mediated cytotoxic effects on the parasites' host cell itself. One possible explanation 
previously raised to explain the cytotoxicity of such saponins on macrophages is that saponins 
are amphiphilic and induce the formation of micelles, which can be easily taken up by 
27phagocytic cells.  
Although other triterpenes have been shown to exhibit antibacterial activity against 
Mycobacterium tuberculosis, this was not the case for saponins 1 or 2 (IC  > 25 µM). 50
Literature reports that the presence of a carbonyl group at the C-16 position of a triterpene 
would be crucial to exhibit anti-mycobacterial activity. For example, protoprimulagenin A, 
bearing a hydroxyl moiety at C-16, displays no antibacterial activity whereas aegicerin, 
having almost the same structure but with a carbonyl group at C-16, exhibits marked 
15antibacterial activity against a large number of resistant Mycobacterium strains.
CT26.WT colon cancer (ATCC code CRL-2638) and the B16F10 melanoma (ATCC code CRL-6475). The 
experiment has been carried once with 6 replicates per experimental condition.
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CONCLUSIONS
- In conclusion, the structures of two known 13,28-epoxy-oleanane triterpene saponins (1, 
2) isolated from two Peruvian Myrsinaceae, Myrsine coriacea and Myrsine andina, were 
elucidated. This is the first report of saponins isolation from these plants. The present 
study demonstrated that compound 1 displayed significant anti-tumor activities towards 
a broad spectrum of human cancer cells. Furthermore, we demonstrated the crucial role 
of the aldehyde function at C-30 for the cytotoxicity. Further experiments should be 
carried out in order to investigate their ability to induce apoptosis in different cancer cell 
lines. These results may be useful in the search for new compounds for cancer prevention 
and therapy. 
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